



Caplin Point Laboratories *Ltd.*

Investor Presentation February 2023

Rated #1 in India for "Most Consistent Profitable Growth across the last 10 years"[#]

Second Largest wealth creator for the decade ending 2020*

[#]Value Research magazine – Wealth Insight June 2022 issue
^{*}The Economic Times



The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Caplin Point Laboratories Ltd.

Content

1 Q3 and 9MFY23 Highlights

2 Understanding Caplin

3 Growth engines of Caplin

4 More about Caplin



Headquarters, Chennai

Content

1 Q3 & 9MFY23 Highlights

- 1.1 Q3 & 9MFY23 Highlights
- 1.2 Update on CAPEX
- 1.3 Robust revenue growth coupled with stable margins
- 1.4 P&L for the Quarter

2 Understanding Caplin

3 Growth engines of Caplin

4 More about Caplin



CP-I plant at Suthukeny, Puducherry

Financial Highlights

- Revenue for **9MFY23** grew by **17.2% YoY** to **Rs. 1,122 Cr**
- **Gross Margins** for 9MFY23 are at **54.8%**
- **EBITDA** for 9MFY23 is **Rs. 362 Cr; EBITDA margins at 32.2%**
- **9MFY23 PAT is at Rs. 276 Cr up 21.1% YoY**
- **Cash and Cash equivalents** at **Rs. 718 Cr** as of 31st December 2022;
- **Cash flow From Operations at Rs 176 Cr for 9M** ended 31st December 2022; **Capex** for 9MFY23 is at **Rs 154 Cr.; Free cash flow** for the period was **Rs 22 Cr**
- **Basic EPS** grew by **24% to Rs. 36.17** in 9MFY23 against Rs. 29.18 in 9MFY22 (not Annualized)
- **Receivable** stood stable around **100 days** as of 31st December 2022
- Geographical breakup of sales: **LATAM & ROW - 86%, US – 14%**

Emerging Markets Business Highlights

- As part of being future ready, Company has **completed expansion in Softgel Capacity to 2x** and **Injectable capacity is being augmented shortly**. Both segments continue to contribute to Company's growth in revenues and profitability.
- **Development of 50+ API's** both in General Category and Oncology **completed at R&D scale**, to be scaled up when Company's API units go on stream which is expected within coming 6 months.
- **Product registration work ongoing for Oncology products in several LatAm markets**, to ensure breakeven is achieved in a shorter period for Company's Oncology facility.
- **Amaris Clinical** (Caplin's CRO wing) successfully **completes BE studies for multiple OSD products**, to be filed in higher surveillance markets such as Chile, in LatAm.
- Company's expansion into newer geographies such as Turkmenistan, Uzbekistan, Vietnam, Cambodia and Philippines ongoing with multiple orders received this Quarter.

US & Regulated Markets Business Highlights

- **Caplin Steriles' (CSL) Total Revenue** in 9MFY23 crosses **Rs. 155 Cr**, with a growth of **70% YoY** and **surpassing last FY's full year sales of 127 Cr**.
- **Revenue breakup is a healthy mix of Product supply and Milestone + Profit Share, with current split at 70:30**
- **With a healthy order book, Company targets finishing current FY with Rs. 200 Cr** in sales and breaking even. Increase in revenues mainly attributed to higher market share from current products.
- Company has **filed 2 ANDAs** in the last Quarter, with **9 ANDAs under review** with FDA as on date. Company **expects approval for 3 products by next Quarter** which will take our total ANDA approved products to 22.
- Company has **completed 4 complex products Exhibit Batches**, which includes **3 Injectables and 1 Ophthalmic**. Plans to file all 4 with US and Global markets during 2023.
- Company on target **to launch its own label in the US by Q1FY24**, for 3 approved products.
- Overall development pipeline remains robust, with **58+ ANDAs under development** with an addressable market in US at over **\$5 Billion**.
- Company's drive towards digitalization continues with installation of e-Log Books at the plant, having already completed installation of Labware LIMS and SAP recently.

Caplin is venturing on a Capex journey of INR ~450-500 Cr. to expand existing capacities, widen its product portfolio and backward integrate majority of the products. All of the planned Capex is funded through internal accruals only

Capacity expansion and Maintenance Capex

Capacity expansion in Caplin Steriles:

- ▶ Phase 2 of the facility nearing completion, commercial batches targeted by Q2FY24 from this unit. Post completion, company will be able to leverage large batches with faster filling speed for Injectable Vials. Also, a Pre-Filled Syringe line has been added, a new delivery system previously not available at Caplin Steriles.
- ▶ Phase 3, a standalone plant close to the current site is expected to be completed within Q3FY24, which will have high Lyophilization capacity, and plans to add differentiated dosage forms such as Inhalations shortly

Capacity Expansion at ROW facility

- ▶ OSD Facility for Global markets – Construction work to commence shortly on new OSD plant in Thervoy SIPCOT, near Chennai. The facility, which is expected to be completed in 12 months, will increase existing OSD capacity by 3x.

~ INR 270 Cr

Oncology

- ▶ Phase 1 involves Oral Solid Dosages and Phase 2 would be Injectables.
- ▶ Oral Solid Dosages nearing completion. Injectable phase to be completed within 9 months.

~ 130 Cr


Backward Integration

- ▶ Company targets being backward integrated with own APIs for 70% of all filings in US by 2024, a critical differentiator for Generic Injectables
- ▶ For this purpose, caplin has acquired an API plant in Vizag, which will be refurbished into a regulated markets compliant plant, for general category APIs. This is part of the Company's backward integration initiative, both for Injectable and OSD APIs.
- ▶ General Category API site refurbishment work ongoing, company targeting completion within 6 months.
- ▶ Oncology API site construction starting in adjacent facility to the Finished Dosages Oncology plant at Kakkalur, Chennai. Targeting completion latest by Q3FY24.


~ INR 100 Cr

Robust revenue growth coupled with stable margins


Total Revenue (INR Cr)






EBITDA (INR Cr)



PAT (INR Cr)



Q3 FY23



9M FY23

P&L for the Quarter – Consolidated

Value (INR Cr)	Q3 FY23	Q3 FY22	YoY (%)	Q2 FY23	QoQ (%)	9M FY23	9M FY22	YoY (%)
Revenue from Operation	372.07	326.20	14.1%	359.05	3.6%	1,077.45	930.17	15.8%
Other Income	14.15	9.54		16.48		44.58	27.24	
Total Revenue	386.22	335.74	15.0%	375.53	2.8%	1,122.03	957.41	17.2%
Cost of Goods sold	163.90	143.84	13.9%	165.48	-1.0%	486.61	405.59	20.0%
Gross Profit	208.17	182.36	14.2%	193.57	7.5%	590.84	524.58	12.6%
<i>Gross Profit Margin (on Rev from Ope)</i>	55.9%	55.9%		53.9%		54.8%	56.4%	
Employee Benefit Expenses	34.54	29.38	17.6%	34.02	1.5%	100.99	85.06	18.7%
Research and Development expenses	18.40	14.69	25.3%	15.15	21.4%	46.07	43.81	5.2%
Other operating expenses	45.86	37.33	22.9%	38.82	18.1%	126.65	100.98	25.4%
Total expenditure	98.80	81.40	21.4%	87.99	12.3%	273.71	229.85	19.1%
EBITDA	123.52	110.50	11.8%	122.06	1.2%	361.71	321.97	12.3%
<i>EBITDA Margin</i>	32.0%	32.9%		32.5%		32.2%	33.6%	
Depreciation and Amortisation	11.43	11.70	-2.3%	11.46	-0.2%	33.86	35.45	-4.5%
EBIT	112.09	98.80	13.5%	110.60	1.3%	327.85	286.52	14.4%
<i>EBIT Margin</i>	29.0%	29.4%		29.5%		29.2%	29.9%	
Finance Cost	0.36	0.14		0.14		0.55	0.62	
Share of Loss in associates	(0.01)	-		0.01		-	-	
Profit Before Tax	111.74	98.66	13.3%	110.45	1.2%	327.30	285.90	14.5%
<i>PBT Margin</i>	28.9%	29.4%		29.4%		29.2%	29.9%	
Tax	14.35	19.38		18.42	-22.1%	51.55	58.28	-11.5%
Profit after Tax	97.39	79.28	22.8%	92.03	5.8%	275.75	227.62	21.1%
<i>PAT Margin</i>	25.2%	23.6%		24.5%		24.6%	23.8%	

Content

1 Q3 & 9MFY23 Highlights

2 Understanding Caplin

2.1 Transformation across the decades

2.2 Caplin's core business

2.3 Diversified Product Portfolio with a balanced product mix

2.4 Smart mix of manufacturing and outsourcing; Product capacities

2.5 Research & Development Capabilities

2.6 Delivered Robust Profitable Growth & Returns over the decade


3 Growth engines of Caplin

4 More about Caplin



CP-IV plant at Gummidipoondi, Chennai

Transformation across the decades



Contract manufacturer

Becoming a responsible pharma company

Market-led Company

Technology and research-led marketing Company

Plain vanilla generic products

Mix of generics, branded generics and specialty molecules and Injectables

Introducing products that plugged marketplace gaps

Launch specialty niche products that Create new markets in varied therapy segments

Negative-working capital business

Selective use of Credit strategy to increase market share and remain cash surplus


2 main geographies 10 countries
(Latin America & Francophone Africa)

Extended to Regulated markets like USA with plans to enter Canada, Australia, China and Brazil shortly.

Our core business – Tapping the untapped markets

Operating Revenue

(9MFY23)




■ Africa ■ US ■ LATAM

Revenue by Business Segment

(Emerging Markets)

(9MFY23)




■ Generic ■ Branded Generic

Revenue by Channel

(Emerging Markets)

(9MFY23)




■ Distributors ■ Direct Sales
■ Tender Business

US Business – Injectables and
Ophthalmic


Emerging Markets (LATAM+Africa) – Generics and Branded Generics

Caplin covers a wide spectrum of pharmaceutical formulations and therapeutic segments across 23 countries with operating revenue of Rs. 1,122 Cr in 9MFY23

Diversified Product Portfolio with zero reliance on single product / Therapy



Changing product mix



Our Products

- ✓ Tablets
- ✓ capsules
- ✓ Injections (liquid & lyophilized, pre-filled syringes)
- ✓ Ophthalmic
- ✓ Liquid Orals
- ✓ Softgel Capsules
- ✓ Ointments, Creams & Gels
- ✓ Powder for injections
- ✓ Suppositories & Ovules
- ✓ Dermocosmetics
- ✓ Surgicals & Disposables
- ✓ Pre-Mix Bag Formulations
- ✓ Inhalers & Sprays
- ✓ IV infusion

Smart mix of manufacturing, outsourcing; product capacities

Exports

55% of the products produced inhouse

45% of the products are outsourced from quality conscious partners in India and China

India
70%

China
30%



Total Annual Product Capacity

1,500 Mn
Tablets

400 Mn
Capsules

12 Mn
Pre-Mix Bags

20 Mn
Liquid Injection in
Ampoules

65 Mn
Liquid Injections in
Vials

6 Mn
Bottles of Liquids

1 Mn
Bottles of Dry
Syrups

12 Mn
Pre-Filled
Syringes

12 Mn
Ophthalmic units

220 Mn
Soft Gels

30 Mn
Suppositories

1.2 Mn
Lyophilized Vials

CP I plant:

Generics and Branded Generics

- Liquid injections in Vials, Ampoules and Pre-Filled Syringes.
- Tablets
- Capsules
- Liquid Orals (Syrup & Suspension)
- Soft Gelatin Capsules
- Suppositories and Ovules

INVIMA and WHO-GMP

Suthukeny, Puducherry

CP IV Plant (Part of Caplin Steriles Limited)

Injectables and Ophthalmic

- Vials
- Lyophilized Vials
- Ophthalmic
- Pre-Mixed Bags
- Pre-Filled Syringes

US FDA, EU-GMP, and INVIMA

Gummidipoondi, Chennai

Caplin's smart strategy of balanced manufacturing and outsourcing makes it possible to be a lean organisation as well as de-risk against cost escalations, currency fluctuations and other headwinds

Research & Development Capabilities

5 Dedicated Facilities

Caplin has 5 dedicated R&D setups (3 – DSIR approved and 2 under approval)

INR 500+ Cr Capex

Continuous capex investment of over INR 500 Cr over last 6 years towards enhanced manufacturing and R&D capabilities


R&D Expense

Total R&D Spends (Capex + Opex) is 19% of FY22 PAT

API


Completed R&D for 50 APIs to be used for backward integration in US and Emerging markets. On track for the DMF filing

R&D expense – Capex + Opex (INR Cr)




Note: FY16 data for 9 months due to change in fiscal year of the company

R&D Team at Caplin (Nos)



ANDA Pipeline




Caplin ranks amongst the top companies in India, for R&D spend as a percentage of Revenue on average in the past 5 years.*


*Source – CNBC-TV18, Dec 31st 2020

Delivered Robust Profitable Growth & Returns over the years


Total Revenue




EBITDA




PAT




Robust Margins



Consistently delivered strong returns



Cash and Cash Equivalent



Target achieved

2016 Top Line is now 2022 Bottom Line

New Target

To achieve a Cash Surplus of Rs.1000 ~ 1500 Cr in the next 5 years

Content

1 Q3 & FY23 Highlights

2 Understanding Caplin

3 Growth Engines of Caplin

4 Appendix



Amaris Clinical - CRO Clinic, Chennai



01

Core business to grow at historical pace...

Caplin's core business which is focused on Latin America and Francophone Africa is expected to grow at above industry-average pace with margins expected to improve with increased branded generics business

02

... with US Business to boost the growth...

Aspiration is to have exceptional compliance record and focus on niche products which continues to be in shortage in US market. Caplin believes US business to be one of its primary engines that will drive growth

03

... backed by enhanced value chain...

Backward and forward integration to help save cost, capture more market and control supply chain which is expected to boost earnings

04

... Strong balance sheet and...

Caplin's DNA of remaining debt-free and self-sustenance is highlighted by increasing cash surplus over the years. Strong Balance sheet of Caplin acts as an anchor for our long-term vision

05

... Expansion into other geographies and widening of the portfolio

Caplin plans to enter more regulated markets such as Canada, Australia, China, Russia/CIS as well as enter the bigger LATAM markets of Mexico and Brazil in the near to medium term horizon

Overview

LATAM


- **No. 1 Indian player in Central America**
- Increased its LATAM footprint from **two countries to 12 countries within a decade**
- Entry into Pharmacy sales through **Healthcare portal**, for higher margins and offtake
- Company has earmarked **Mexico and Chile as the next immediate avenues for growth** in LatAm. Company has 1 product approved in Mexico, with 6 more approvals expected in the next few quarters. Company currently has 75 product registrations in Chile.

Africa

- **One of the first few Indian pharmaceutical companies to extend to West Africa** with Brand Marketing
- **High Recognition** of CPL's brands across Francophone Africa

Performance

Operating Revenue from LATAM + Africa (INR Cr)



*FY16 was only 9 months due to change in fiscal year of the company and therefore the FY16 numbers are Annualized

Expansion

- ✓ Increasing focus to larger Latin American countries such as Chile, Colombia and expansion in Mexico and Brazil
- ✓ Working on additional 150 formulations specifically targeting 3 expansion areas – Hospital Injectables, Neuropsychiatric products in Brand Marketing and Anti-Cancer products.

Pharmacy automation

- ✓ To increase profitability and augment strong capabilities in the Supply Chain.
- ✓ 'QuetenX', part of 10X Healthcare portal, continues to show strong traction, reaching 1,000+ unique B2B customers in Latin America

Strategy



End to end business model

- ✓ Acquisition of distributors in LATAM region creates an end-to-end business model

Bottom of the Pyramid

- ✓ Continued focus on the Bottom of the Pyramid, creating a stickiness factor for Caplin's products

Quétenx B2B E-Commerce Sales 2022



Quétenx is the first B2B Marketplace in Central America for Online Pharmacy Purchases

E-Commerce Pipeline - LATIN AMERICA



Highlights JAN-DEC 2022

▲ USD **2.6MM** Driven Sales through digital channel 2022
 ▲ **1k+** Unique Customers
 ▲ **13k** Orders through digital channel

USD **211k**
Monthly Average 2022

383 SKUs
Monthly Average 2022

Overview

- **Invested ~Rs.450 Crore in Capex and Opex** for the 5 years since 2014 through internal accruals to enter the US and Regulated markets
- **Entered US Market in 2017-18** with launch of Ketorolac Inj, currently owned by **Baxter. Launched 15 products in total in the US**, through partners such as Fresenius Kabi, Baxter, Sagent, Xellia, Somerset, Meitheal and others.
- **Caplin received approval from Brazil's ANVISA for Injectable plant through mutual recognition of US FDA EIR.**
- Company has made significant progress towards digitalization of all Quality processes with the **implementation of the Labware LIMS system.**
- Non-US markets: 5 products filed in Canada and Mexico, 3 in Australia, 2 in South Africa, and 1 each in EU and China.

Injectable plant Inspection history

Plant has undergone 3 US FDA, 2 EU GMP audits and 1 ANVISA successfully since 2015

Date	Authority	Observations/ 483 / Warning letter
Aug 2021	ANVISA	No observations
June 2019	USFDA	2 observations of procedural nature
October 2018	USFDA	No observations
October 2016	USFDA	2 observations of procedural nature
May 2015	EU GMP	No Critical observations
Sep 2018	EU GMP	No Critical observations

Creating the brand Caplin in US market

- ✓ Strengthening the US Credentials by entering niche high value Injectable and Ophthalmic segment
- ✓ Filing a mix of Simple and Complex injectables in US under Caplin's name
- ✓ Planning to have front-end presence by Q4FY23 in the US market to launch own label & expand.

Focused on a niche segment

- ✓ The Company believes in focusing on this niche segment as there's a chronic gap between demand and supply in Injectables in the US market, resulting in frequent shortages. Injectables have seen lesser price erosion comparatively due to these shortages.

Strategy


Strategic Partner

- ✓ Fidelity invested INR 218 Cr. in Caplin Steriles (Caplin's US business) for minority stake.
- ✓ Fidelity is known to be a long-term knowledge partner with over 50% of worldwide private investments into Healthcare. This helps bringing us access to a powerful investment platform spanning Asia, Europe and the US.

Capacity expansion & backward integration

- ✓ 3x Capacity expansion ongoing at Caplin Steriles Plant – CP-4
- ✓ API backward integration plan for US business is on track
- ✓ **Expansion into Pre-Mix Bags, Lyophilized Vials and Pre-Filled Syringes soon**

Transaction Structure



Transaction Details

Objective

- Increase R&D capabilities to include Complex Injectable and Ophthalmic products portfolio and enhance capacities at Plant.
- **Eight Roads and F-Prime Capital – Fidelity** together bring access to a powerful investment platform spanning **Asia, Europe and the US**.

Key Transaction Highlights

- Caplin Steriles Ltd, subsidiary of Caplin Point Laboratories Ltd. will cater to the rapidly growing demand for **injectable products** in the regulated markets, especially the **US and other Regulated Markets**.
- **Eight Roads Ventures and F-Prime Capital** invests **INR 218Cr for Minority** stake, with cash infusion coming into Caplin Steriles Ltd.
- **Fidelity** known to be a long term knowledge partner with over 50% of worldwide private investments into Healthcare.
- The subsidiary has already filed **28 ANDAs** on its own and through partners with the **US FDA**, with **19 approvals till date**.

\$670mn

Market size of our products approved and under approval

\$5 Bn+

Overall market size of our products in Pipeline, under approval and approved

Overall market opportunity for Caplin in near future in US is about ~ \$5 Bn+

Our strategic decisions which will help us in scaling up value chain

Plant to Portal

- Proposed extension from product manufacture to retail interface through Healthcare portal automating pharmacies, clinics and diagnostic labs.
- This deployment of healthcare portal would generate big data for generics which will lead to better product positioning and insights

1

Direct approach

- Direct marketing to pharmacies and wholesalers; circumventing trade channels. Currently 20% revenue is generated from direct sales.

Widen interface

- With 15,000 pharmacies to address bottom-of-the-pyramid customers and engage with doctors

2

Forward integration

- Caplin moves further up the Value Chain with acquisition of its Channel partners at Latin America.
- Thereby controlling manufacturing, export, import, distribution with direct access to retailers and wholesalers.

3

Backward integration

- API Plant will cater to US and LATAM business as well as upcoming Oncology business.
- Backward integration into API for complex injectable products
- Targeting complete backward integration from Key Starting Material (KSM) to Intermediates and API.

4


Setting up of CRO

- CRO wing of Caplin Point will cover BE/BA studies for captive consumption, before scaling up as a commercial CRO
- Target markets are China, US, EU and LATAM
- Company's CRO wing Amaris Clinical completes back-to-back virtual and physical US FDA audits, **EIR received for the first inspection.**

5

These strategic decisions which will help caplin to have a better cost advantage is future, gather better intel on the market it operates in, better understand the market trends and changing customer needs as well as better access to some of its markets

Amaris Clinical – Highlights



Regulatory approvals



Regulatory clearance targeted



State of the Art Technology

Andrew Alliance - Auto Pipetting System



The pipetting robot. This liquid handling robot ensures fully traceable and reproducible experiments by automation of complete laboratory workflows – using conventional pipettes and labware


Hamilton Automated Sample Access Manager (Sam HD)



- ✓ A first of its kind in India, SAM HD is a completely automated sample management system ensuring high integrity and speed of processing
- ✓ Amaris Clinical is the first CRO in India to have this Automated Storage System


Caplin's strong balance sheet acts as an anchor for its vision of perceiving an 'Invisible opportunity'

Receivable Days




Stable Receivables over the recent period

Total Capex (INR Cr)



Caplin has incurred strong capex in recent years to enable future growth for next 5 years

Fixed Asset Turnover Ratio



Company has maintained optimal asset turnover ratio over the years

Caplin had acquired most of its Channel partners in Latin American markets

Caplin is a net debt free company

Caplin is expanding its presence in regulated countries, larger markets of Latin America, Russia/CIS markets, China, and other Asian Countries

Content

1 Q3 & 9MFY23 Highlights

2 Understanding Caplin

3 Growth engines of Caplin

4 More about Caplin

4.1 Experienced and Visionary Board of Directors

4.2 Shareholder Information



R&D centre



Mr. C.C. Paarthipan
Chairman

- ✓ 30+ Years of experience in the pharmaceutical industry
- ✓ Spearheading the group in its multi-pronged growth approach
- ✓ First Gen Entrepreneur with a focus towards bottom of the pyramid



Dr. Sridhar Ganesan
Managing Director

- ✓ 35+ Years experience in Pharmaceutical Industry
- ✓ Previously, held leadership positions in several international assignments
- ✓ The Government of India's Pharmaceutical Export Promotion Council of India has designated him as an "Honorary Expert"
- ✓ Has been a Faculty in BITS



Dr. R Nagendran
Independent Director

- ✓ Ph.D in Ecology and Ethology and M.SC in Zoology
- ✓ Former Expert Member of the National Green Tribunal and former Head of Department of Environmental Science in St. Joseph's College, Bangalore.



Mr S Deenadayalan
Independent Director

- ✓ Post Graduate degree in Social Work from Madras School of Social Work and Under Graduate degree in Sociology from Annamalai University
- ✓ Has extensively worked and mentors individuals enabling them to become successful professionals and more than 30,000 municipal school students have been benefitted by his idealistic model.



D Sathyanarayanan
Independent Director

- ✓ 30+ years experience in application dev. & implementation
- ✓ MS from Stanford University and bachelors from IIT-Madras



Dr. C K Gariyali, IAS
Independent Director

- ✓ Retired IAS Officer and holds a Doctorate in Women Studies
- ✓ Was Principal Secretary to the Governor of Tamil Nadu from 2005-08
- ✓ Was Secretary to Hon'ble CM of Tamil Nadu
- ✓ Worked with various International Agencies like World Bank etc.



Mr V Thirumalai
Independent Director


- ✓ 50+ years experience in the field of finance, HR, management & industrial relations
- ✓ Post Graduate in Commerce



R Viswanathan
Independent Director

- ✓ Retired ambassador of India to Argentina, Uruguay & Paraguay – 2007 to 2012
- ✓ Latin American expert, widely renowned for his initiatives bringing Latin America closer to India.

Caplin Shareholding as on 31st December 2022





Share Information (as on 31st December 2022)

NSE Ticker	CAPLIPOINT
BSE Ticker	524742
Market Cap (INR Cr)	5,407
% free-float	31.2%
Free-float market cap (INR Cr)	1,687
Total Debt (INR Cr)	9.7
Cash & Cash Equivalents (INR Cr)	718
Shares Outstanding	7,58,92,246
3M ADTV (Shares)*	48,290
3M ADTV (INR Cr)*	3.6
Industry	Pharmaceuticals

*Source: NSE & BSE

Our Products





Caplin Point Laboratories Limited

Investor Relations at Caplin

Mr G Venkatram
investors@caplinpoint.net

Ernst & Young
Rahul Thakur
rahul.thakur@in.ey.com

BSE

524742



NSE CAPLIPPOINT

CIN: L24231TN1990PLC019053 | ISIN: INE475E01026 | DUNS:86-148-4556 | WWW.CAPLINPOINT.NET

©2018, Caplin Point Laboratories Limited – All Rights Reserved.

© 2018 Caplin Point Laboratories Limited, All Rights Reserved.

“Caplin Point” and The Caplin Point Logo are trademarks of Caplin Point Laboratories Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.